- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07209462
- Original Trial
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of MRM-3379 in Male Participants With Fragile X Syndrome
This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive). In addition, a parallel cohort of participants ages 13 to <16 will receive open-label MRM-3379. All participants will participate for 12 weeks of treatment. The study is also intended as a proof-of-concept investigation to evaluate whether MRM-3379 can improve FXS symptoms
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08950
- Recruiting
- Sant Joan De Deu Barcelona Hospital
-
Contact:
- Ana Gutierrez
- Phone Number: 80947 607-797-244
- Email: ana.gutierrezg@sjd.es
-
Contact:
- Genís Oña Esteve
- Phone Number: 80948 607-799-616
- Email: genis.ona@sjd.es
-
Principal Investigator:
- Mercedes Serrano Gimare
-
Barcelona, Spain, 08208
- Recruiting
- Parc Tauli Hospital Universitari
-
Contact:
- Aida Gonzalez
- Phone Number: 80817 +34 93 723 10 10
- Email: agonzalezru01@tauli.cat
-
Principal Investigator:
- Ana Roche-Martinez
-
Málaga, Spain, 29009
- Recruiting
- Hospital Regional Universitario de Málaga (H. Civil)
-
Contact:
- Jonathan Dawood
- Phone Number: +34 620 25 35 35
- Email: jonathanjosepd@gmail.com
-
Principal Investigator:
- Jesús Herrera- Imbroda
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Recruiting
- Southwest Autism Research & Resource Center
-
Principal Investigator:
- Christopher Smith
-
Contact:
- Riley Stark
- Phone Number: 480-351-0567
- Email: rstark@autismcenter.org
-
Contact:
- Padmaja Lakamsani
- Email: PLakamsani@autismcenter.org
-
-
California
-
Irvine, California, United States, 92604
- Recruiting
- Amnova Clinical Research, LLC
-
Contact:
- Maggie Wang
- Phone Number: 949-358-7447
- Email: maggie@amnovaresearch.com
-
Principal Investigator:
- Gary Feldman
-
Contact:
- Jannet Guerrero
- Phone Number: 949-861-7479
- Email: jannet.guerrero@amnovaresearch.com
-
Orange, California, United States, 92868
- Recruiting
- Children's Hospital of Orange County - Pediatric Subspecialty
-
Principal Investigator:
- Sailaja Golla
-
Contact:
- Adrienne Moore
- Phone Number: 714-288-7456
- Email: Adrienne.Moore@choc.org
-
Contact:
- Stanley Friers
- Phone Number: (714) 288-7683
- Email: Stanley.Friers@choc.org
-
Sacramento, California, United States, 95817
- Recruiting
- Uc Davis Mind Institute
-
Contact:
- Melissa Heys
- Phone Number: 916-703-0301
- Email: meheys@health.ucdavis.edu
-
Contact:
- Abigail Borbe
- Phone Number: 916-703-0281
- Email: amoradelhigareda@health.ucdavis.edu
-
Principal Investigator:
- Randi Hagerman
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
Principal Investigator:
- Nicole Tartaglia
-
Contact:
- Nicole Tartaglia
- Phone Number: 720-777-6895
- Email: Nicole.Tartaglia@childrenscolorado.org
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- Neurology
-
Principal Investigator:
- Barbara Coffey
-
Contact:
- Dr. Barbara Coffey
- Phone Number: 305-243-2759
- Email: bjc134@miami.edu
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University - The Emory Clinic - Clifton Road
-
Contact:
- Robin Vinson
- Phone Number: 404-778-8533
- Email: robin.vinson@emory.edu
-
Principal Investigator:
- Amy Talboy
-
Contact:
- Nadia Ali
- Phone Number: 404-778-8613
- Email: nadia.ali@emory.edu
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Rush University Medical Center-Clinical Operation
-
Principal Investigator:
- Elizabeth Berry-Kravis
-
Contact:
- Lorelai Konen
- Phone Number: 312-942-2815
- Email: Lorelai_Konen@rush.edu
-
Contact:
- Molly Flanagan
- Phone Number: 312-942-1876
- Email: Molly_L_Flanagan@rush.edu
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Recruiting
- Kennedy Krieger Institute, John Hopkins School of Medicine
-
Principal Investigator:
- Stephanie Morris
-
Contact:
- Kennedy Krieger
- Phone Number: 443-923-3850
- Email: ResearchTrials@KennedyKrieger.org
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Boston Children's Hospital
-
Principal Investigator:
- Lisa Prock
-
Contact:
- Michelle Coughlin
- Phone Number: 857-218-3842
- Email: michelle.Coughlin@childrens.harvard.edu
-
Contact:
- Katherine Pawlowski
- Phone Number: 857-218-5472
- Email: Katherine.pawlowski@childrens.harvard.edu
-
Worcester, Massachusetts, United States, 01655
- Recruiting
- UMass Memorial Health
-
Contact:
- Taylor Merk
- Phone Number: 774-455-4119
- Email: Taylor.merk@umassmed.edu
-
Contact:
- Lauren Venuti
- Phone Number: 774-455-4113
- Email: Lauren.venuti@umassmed.edu
-
Principal Investigator:
- Isha Jalnapurkar
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55414
- Recruiting
- University of Minnesota Department of Medicine
-
Contact:
- Brittany Faanes
- Phone Number: 612-625-5929
- Email: Grego318@umn.edu
-
Principal Investigator:
- Amy Esler
-
Contact:
- Rachel Floersch
- Phone Number: 612-626-8424
- Email: Floer013@umn.edu
-
-
Ohio
-
Cincinnati, Ohio, United States, 42229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Principal Investigator:
- Rana Elmaghraby
-
Contact:
- Hannah Sachs
- Phone Number: 513-803-1150
- Email: Hannah.Sachs@cchmc.org
-
Contact:
- Priya Ramesh
- Phone Number: 513-636-4433
- Email: Priya.Ramesh@cchmc.org
-
-
Pennsylvania
-
Media, Pennsylvania, United States, 19063
- Recruiting
- Suburban Research Associates
-
Principal Investigator:
- Kristen Dopf
-
Contact:
- Naya Square
- Phone Number: 1128 610-891-9024
- Email: Nsquare@suburbanresearch.com
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Not yet recruiting
- Intermountain Healthcare - Park City Specialty Clinic
-
Principal Investigator:
- Victoria Wilkins
-
Contact:
- Peter Farr
- Phone Number: 801-587-2103
- Email: peter.farrell@hsc.utah.edu
-
Contact:
- Karina Mattson
- Phone Number: 801-587- 7573
- Email: karina.mattson@hsc.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to provide signed informed consent/assent. Where local regulations permit inclusion of participants deemed unable to provide informed consent, a legally authorized representative must provide informed consent on the participant's behalf, and the participant must provide assent if applicable.
- Male, 13-45 years of age (inclusive)
- Weight ≥30 kg and BMI between 18 and 36 kg/m2 (inclusive) at the screening visit
- Diagnosis of FXS with a molecular genetic ≥200 CGG repetitions .
- Able to perform the PVT and ORRT of the NIH-TCB
- Have a consistent caregiver(s) who is willing and able to be present regularly and reliably with the participant
- Able to swallow tablets or capsules
Exclusion Criteria:
History of or current medical condition other than FXS and related issues that would place the participant at higher risk from study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm 1: Low Dose of MRM-3379
Participants 16-45 years of age randomized to this arm will receive the low dose of MRM-3379 |
Oral capsule |
|
Experimental: Arm 2: Middle dose of MRM-3379
Participants 16-45 years of age randomized to this arm will receive the middle dose of MRM-3379 |
Oral capsule |
|
Experimental: Arm 3: High dose of MRM-3379
Participants 16-45 years of age randomized to this arm will receive the high dose of MRM-3379 |
Oral capsule |
|
Placebo Comparator: Arm 4 :Placebo
Participants 16-45 years of age randomized to this arm will receive Placebo |
Capsules matched to study drug without the active pharmaceutical ingredient |
|
Experimental: Arm 5: Low dose of MRM-3379 Open-Label
Participants 13 to < 16 years of age will receive the low dose of MRM-3370 Open-Label |
Oral capsule |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence and severity of treatment-emergent adverse events and Withdrawal due to adverse events and withdrawal due to adverse events
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Genetic Diseases, Inborn
- Neurobehavioral Manifestations
- Congenital Abnormalities
- Heredodegenerative Disorders, Nervous System
- Intellectual Disability
- Genetic Diseases, X-Linked
- Sex Chromosome Disorders
- Chromosome Disorders
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- X-Linked Intellectual Disability
- Fragile X Syndrome
Other Study ID Numbers
- ENV-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.